High-dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft-tissue sarcoma

1983 ◽  
Vol 11 (2) ◽  
Author(s):  
RobinC. Stuart-Harris ◽  
PeterG. Harper ◽  
ColinA. Parsons ◽  
StanleyB. Kaye ◽  
CarolA. Mooney ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Dose ◽  
Advanced Soft Tissue Sarcoma

High dose ifosfamide, doxorubicin, dacarbazine and G-CSF for patients with metastatic or locally advanced soft tissue sarcoma

1999 ◽  
Vol 11 (3) ◽  
pp. 200-203
Author(s):  
Lin Tong-yu ◽  
Guang Zhong-zhen ◽  
Su Yi-sun ◽  
Zhou Zhong-mei ◽  
Liu Dong-geng
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Locally Advanced ◽  
High Dose ◽  
Advanced Soft Tissue Sarcoma

Efficacy of Sequential High-Dose Doxorubicin and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for Research on Sarcomas

2009 ◽  
Vol 27 (11) ◽  
pp. 1893-1898 ◽  
Author(s):  
Joan Maurel ◽  
Antonio López-Pousa ◽  
Ramón de las Peñas ◽  
Joaquín Fra ◽  
Javier Martín ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
Standard Dose ◽  
Performance Status ◽  
Single Agent ◽  
Eastern Cooperative Oncology Group ◽  
High Dose ◽  
Open Label ◽  
Advanced Soft Tissue Sarcoma ◽  
Ecog Performance Status

Purpose To assess the progression-free survival (PFS) and antitumor response to standard-dose doxorubicin compared with sequential dose-dense doxorubicin and ifosfamide in first-line treatment of advanced soft tissue sarcoma. Patients and Methods Patients with measurable advanced soft tissue sarcoma, Eastern Cooperative Oncology Group (ECOG) performance status (PS) < 2, between the ages 18 and 65 years, and with adequate bone marrow, liver, and renal function were entered in the study. The stratifications were: ECOG PS (0 v 1), location of metastases, and potentially resectable disease. Patients were randomly assigned to either doxorubicin 75 mg/m2 given as a bolus injection every 3 weeks for 6 cycles (arm A) or doxorubicin at 30 mg/m2 per day for 3 consecutive days once every 2 weeks for 3 cycles followed by ifosfamide at 12.5 g/m2 delivered by continuous infusion over 5 days once every 3 weeks for 3 cycles with filgastrim or pegfilgastrim support (arm B). Results Between December 2003 and September 2007, 132 patients were entered onto the study. Febrile neutropenia, asthenia, and mucositis were more frequent in the arm B. The interim preplanned analysis for futility allowed the premature closure. Objective responses were observed in 23.4% of assessable patients in arm A and 24.1% in arm B. PFS was 26 weeks in the arm A and 24 weeks in arm B (P = .88). Overall survival did not differ between the two therapeutic arms (P = .14). Conclusion Single-agent doxorubicin remains the standard treatment in fit patients with advanced soft tissue sarcoma.

Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma

1997 ◽  
Vol 33 (2) ◽  
pp. 220-225 ◽  
Author(s):  
S. Jelić ◽  
V. Kovc̆in ◽  
N. Milanović ◽  
N. Babović ◽  
M. Kreac̆ić ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Dose ◽  
Advanced Soft Tissue Sarcoma ◽  
Randomised Study

High-dose ifosfamide by infusion with mesna in advanced soft tissue sarcoma

1983 ◽  
Vol 10 ◽  
pp. 163-164 ◽  
Author(s):  
R. Stuart-Harris ◽  
P.G. Harper ◽  
S.B. Kaye ◽  
E. Wiltshaw
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Dose ◽  
Advanced Soft Tissue Sarcoma

High-Dose Epirubicin-Cisplatin Chemotherapy for Advanced Soft Tissue Sarcoma

1990 ◽  
Vol 76 (5) ◽  
pp. 467-471 ◽  
Author(s):  
Svetislav Jelić ◽  
Labuda Vuletić ◽  
Nenad Milanović ◽  
Zoran Tomašević ◽  
Vladimir Kovčin
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcoma ◽  
High Dose ◽  
Advanced Soft Tissue Sarcoma
Sign in / Sign up

Export Citation Format

Share Document